OMERACT 9
International Consensus Conference on Outcome Measures in Rheumatology
Kananaskis Village, Alberta, Canada
May 27-31, 2008
Introduction
P. Tugwell, M. Boers, V. Strand, L.S. Simon, P. Brooks .........1767
PDF
Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in RA: A Systematic Literature Search on 5 Candidate Biomarkers
S.W. Syversen, R. Landewé, D. van der Heijde, et al .........1769
PDF
Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in RA, PsA, and Spondyloarthritis: The OMERACT 9 v2 Criteria
W.P. Maksymowych, R. Landewé, P-P. Tak, et al .........1785
PDF
Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in RA, PsA, and AS, and Recommendations for Study Design
W.P. Maksymowych, O. Fitzgerald, G.A. Wells, et al .........1792
PDF
Synovial Tissue Sublining CD68 Expression Is a Biomarker of Therapeutic Response in RA Clinical Trials: Consistency Across Centers
B. Bresnihan, E. Pontifex, R.M. Thurlings, et al .........1800
PDF
The OMERACT MRI Inflammatory Arthritis Group: Advances and Future Research Priorities
P.G. Conaghan, P. Bird, F. McQueen, et al .........1803
PDF
Reducing Invasiveness, Duration, and Cost of MRI in RA by Omitting IV Contrast Injection — Does It Change the Assessment of Inflammatory and Destructive Joint Changes by the OMERACT RAMRIS?
M. Østergaard, P.G. Conaghan, P. O’Connor, et al .........1806
PDF
Testing an OMERACT MRI Scoring System for Peripheral PsA in Cross-sectional and Longitudinal Settings
F. McQueen, M. Lassere, A. Duer-Jensen, et al .........1811
PDF
The OMERACT PsA MRI Scoring System (PsAMRIS): Definitions of Key Pathologies, Suggested MRI Sequences, and Preliminary Scoring System for PsA Hands
M. Østergaard, F. McQueen, C. Wiell, et al.........1816
PDF
Multiple Computer-based Methods of Measuring JSW Can Discriminate Between Treatment Arms in the COBRA Trial — Update of an Ongoing OMERACT Project
J.T. Sharp, J. Angwin, M. Boers, et al .........1825
PDF
The OMERACT Ultrasound Task Force — Advances and Priorities
M-A. D’Agostino, P.G. Conaghan, E. Naredo, et al .........1829
PDF
The OMERACT Initiative. Towards a Reference Approach to Derive QALY for Economic Evaluations in Rheumatology
A. Boonen, A. Maetzel, M. Drummond, et al ......... 2045
PDF
Variation in Outcome Measures in Hip and Knee Arthroplasty Clinical Trials: A Proposed Approach to Achieving Consensus
D.L. Riddle, P.W. Stratford, J.A. Singh, C.V. Strand .........2050
PDF
The OMERACT-ICF Reference Group: Integrating the ICF into the OMERACT Process: Opportunities and Challenges
A. Boonen, G. Stucki, W. Maksymowych, A.C. Rat, R. Escorpizo, M. Boers, and the OMERACT-ICF Reference Group .........2057
PDF
Progress in Assessing Physical Function in Arthritis: PROMIS Short Forms and Computerized Adaptive Testing
J.F. Fries, D. Cella, M. Rose, E. Krishnan, B. Bruce .........2061
PDF
Patient Perspective on Outcomes in Rheumatology — A Position Paper for OMERACT 9
J.R. Kirwan, S. Newman, P.S. Tugwell, G.A. Wells .........2067
PDF
Progress on Incorporating the Patient Perspective in Outcome Assessment in Rheumatology and the Emergence of Life Impact Measures at OMERACT 9
J.R. Kirwan, S. Newman, P.S. Tugwell, et al .........2071
PDF
Assessing Quality of Sleep in Patients with RA
G.A. Wells, T. Li, J.R. Kirwan, et al .........2077
PDF
Responsiveness of the Effective Consumer Scale (EC-17)
N. Santesso, T. Rader, G.A. Wells, et al .........2087
PDF
Assessing Single Joints in Arthritis Clinical Trials
H.I. Keen, C.O. Bingham III, L.A. Bradley, et al .........2092
PDF
OARSI/OMERACT Criteria of Being Considered a Candidate for Total Joint Replacement in Knee/Hip OA as an Endpoint in Clinical Trials Evaluating Potential DMOAD
M. Dougados, G. Hawker, S. Lohmander, et al .........2097
PDF
Measuring Worker Productivity: Frameworks and Measures
D. Beaton, C. Bombardier, R. Escorpizo, et al .........2100
PDF
Observations from the OMERACT Drug Safety Summit, May 2008
L.S. Simon, C.V. Strand, M. Boers, P.M. Brooks, D. Henry, P.S. Tugwell .........2110
PDF
How to Ascertain Drug Safety in the Context of Benefit. Controversies and Concerns
L.S. Simon, C.V. Strand, M. Boers, et al .........2114
PDF
Fibromyalgia Syndrome Module at OMERACT 9: Domain Construct
P. Mease, L.M. Arnold, E.H. Choy, et al, on behalf of the OMERACT Fibromyalgia Working Group .........2318
PDF
Content and Criterion Validity of the Preliminary Core Dataset for Clinical Trials in Fibromyalgia Syndrome
E.H. Choy, L.M. Arnold, D.J. Clauw, et al .........2330
PDF
Developing a Standardized Definition for Disease “Flare” in RA (OMERACT 9 Special Interest Group)
C.O. Bingham III, C. Pohl, T.G. Woodworth, et al .........2335
PDF
Outcome Domains for Studies of Acute and Chronic Gout
H.R. Schumacher, W. Taylor, L. Edwards, et al.........2342
PDF
Progress in Measurement Instruments for Acute and Chronic Gout Studies
R. Grainger, W.J. Taylor, N. Dalbeth, et al.........2346
PDF
Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS)
D. Khanna, O. Distler, J. Avouac, et al .........2356
PDF
Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9
P.A. Merkel, K. Herlyn, A.D. Mahr, et al .........2362
PDF